ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

While antibiotics given in the first week of life reduce vaccine responses at 15 months, probiotics might counteract these ...

Meningococcal disease is a rare but deadly disease caused by the bacterium Neisseria meningitidis. The disease can progress quickly and take the life of a child within 24 hours. Menactra vaccine was ...

Prior to LP, the safety of the procedure should be assessed. A negative CSF test does not rule out IMD, and it has no bearing on the diagnosis of meningococcal septicemia without meningeal invasion.

. The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast ...

The Centers for Disease Control and Prevention (CDC) has recently updated its vaccine recommendations for three critical diseases: meningococcal, respiratory syncytial virus (RSV), and chikungunya.

and Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). On 14 February 2025, the US Food and Drug Administration (FDA) approved GSK’s MenABCWY ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...

This had led vaccine advocates to increase their push for people to get their shots to stop the spread of infectious disease. That includes Jo Larson of Billings, who loves to knit, crochet and read.

Meningococcal serogroup C conjugate (MCC) vaccines are safe and effective. In England and Wales, MCC vaccine programs resulted in substantial herd immunity, as shown by reductions in serogroup C ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...